During the last session, Intensity Therapeutics Inc (NASDAQ:INTS)’s traded shares were 4.04 million, with the beta value of the company hitting 4.02. At the end of the trading day, the stock’s price was $0.39, reflecting an intraday gain of 24.00% or $0.08. The 52-week high for the INTS share is $5.10, that puts it down -1207.69 from that peak though still a striking 25.64% gain since the share price plummeted to a 52-week low of $0.29. The company’s market capitalization is $7.16M, and the average intraday trading volume over the past 10 days was 1.24 million shares, and the average trade volume was 279.32K shares over the past three months.
Intensity Therapeutics Inc (NASDAQ:INTS) trade information
Intensity Therapeutics Inc (INTS) registered a 24.00% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 24.00% in intraday trading to $0.39, hitting a weekly high. The stock’s 5-day price performance is 3.73%, and it has moved by -35.21% in 30 days. Based on these gigs, the overall price performance for the year is -92.30%. The short interest in Intensity Therapeutics Inc (NASDAQ:INTS) is 0.16 million shares and it means that shorts have 0.44 day(s) to cover.
The consensus price target of analysts on Wall Street is $5, which implies an increase of 92.2% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $5 respectively. As a result, INTS is trading at a discount of -1182.05% off the target high and -1182.05% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.29%. While earnings are projected to return 43.38% in 2025, the next five years will return 17.65% per annum.
INTS Dividends
Intensity Therapeutics Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Intensity Therapeutics Inc (NASDAQ:INTS)’s Major holders
Intensity Therapeutics Inc insiders own 33.62% of total outstanding shares while institutional holders control 14.16%, with the float percentage being 21.34%.
Also, the Mutual Funds coming in first place with the largest holdings of Intensity Therapeutics Inc (INTS) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund. Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 190.07 shares. This amounts to just over 1.03 percent of the company’s overall shares, with a $73938.0 market value. The same data shows that the other fund manager holds slightly less at 43.6, or about 0.24% of the stock, which is worth about $16958.0.
